Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: Results from the SILVHIA study

Journal of Human Hypertension

Volumn 21, Issue 12, 2007, Pages 956-965

  Malmqvist, K ^a   Kahan, T ^a   Edner, M ^a   Bergfeldt, L ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; GEOMETRY; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HEART REPOLARIZATION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; TREATMENT DURATION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BIPHENYL COMPOUNDS; DIASTOLE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POTASSIUM; SINGLE-BLIND METHOD; SODIUM; SUPINE POSITION; SYSTOLE; TETRAZOLES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 36448940121     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002250     Document Type: Article

References (45)

1. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-341.
2. Messerli FH. Hypertension and sudden cardiac death. Am J Hypertens 1999; 12: 181S-188S.
3. Aronson R. Mechanisms of arrhythmias in ventricular hypertrophy. J Cardiovasc Electrophysiol 1991; 2: 249-261.
4. Hart G. Cellular electrophysiology in cardiac hyper-trophy and failure. Cardiovasc Res 1994; 28: 933-946.
5. Pacifico A, Henry PD. Structural pathways and prevention of heart failure and sudden death. J Cardiovasc Electrophysiol 2003; 14 764-775.
6. Marbán E. Heart failure: The electrophysiologic connection. J Gardiovasc Electrophysiol 1999; 10: 1425-1428.
7. Roden DM. Long QT syndrome: Reduced repolarization reserve and the genetic link. J Intern Med 2006; 259: 59-69.
8. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994; 343: 327-329.
9. Perkiomäki JS, Huikuri HV, Koistinen JM, Makikallio T, Castellanos A, Myerburg RJ. Heart rate variability and dispersion of QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction. J Am Coll Cardiol 1997; 30: 1331-1338.
10. Sadanaga T, Ogawa S, Okada Y, Tsutsumi N, Iwanaga S, Yoshikawa T et al. Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy. Am Heart J 1993; 126: 114-121.
11. Okada Y, Ogawa S, Sadanaga T, Mitamura H. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-h Holter electrocardiography. J Am Coll Cardiol 1996; 27: 84-89.
12. Savelieva I, Yap YG, Yi G, Guo XH, Hnatkova K, Camm AJ et al. Relation of ventricular repolarization to cardiac cycle length in normal subjects, hypertrophic cardiomyopathy, and patients with myocardial infarction. Clin Cardiol 1999; 22: 649-654.
13. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L et al. Regressión of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-1176.
14. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
15. Karpanou EA, Vyssoulis GP, Psichogios A, Malakou C, Kyrozi EA, Cokkinos DV et al. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J 1998; 136: 765-768.
16. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: Results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA). Am J Cardiol 2002; 90: 1107-1112.
17. Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, et al., LIFE Study Investigators. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: The Losartan Intervention For Endpoint reduction (LIFE) study. Am Heart J 2003; 145: 919-925.
18. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-1793.
19. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
20. Krumholz FIM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879-884.
21. Zabel M, Lichtlen PR, Haverich A, Franz MR. Comparison of ECG variables of dispersion of ventricular repolarization with direct myocardial repolarization measurements in the human heart. J Cardiovasc Electrophysiol 1998; 9: 1279-1284.
22. Bergfeldt L, Melander H, Schenck-Gustafsson K. Time-dependent variation in the cardiac conduction system assessed in young healthy individuals at weeks' interval: Implications for clinical trials. J Am Coll Cardiol 1991; 18: 792-800.
23. Nowinski K, Bergfeldt L. The 'normal' response of the QT interval and QT dispersion following intravenous injection of the sodium-channel blacker disopyramide - methodological aspects. Cardiovasc Drugs. Ther 1995; 9: 573-580.
24. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114 345-352.
25. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004; 43: 731-738.
26. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1996; 78: 197-202.
27. Silverman ME, Pressel MD, Brackett JC, Lauria SS, Gold MR, Gottlieb SS. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol 1995; 75: 460-464.
28. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens 2001; 19: 1883-1891.
29. Gavras I, Gavras H. The antiarrhythmic potential of angiotensin II antagonism: Experience with losartan. Am J Hypertens 2000; 13 512-517.
30. De Mello WC. Cardiac arrhythmias: The possible role of the renin-angiotensin system. J Mol Med 2001; 79: 103-108.
31. Emdad L, Uzzaman M, Takagishi Y, Honjo H, Uchida T, Severs NJ et al. Gap junction remodeling in hypertrophied left ventricles of aortic-banded rats: Prevention by angiotensin II type 1 receptor blockade. J Mol Cell Cardiol 2001; 33: 219-231.
32. Schwieler JH, Kahan T, Nussberger J, Hjemdahl P. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. Am J Physiol 1993; 264: E631-E637.
33. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
34. Varo N, Etayo JC, Zalba. G, Beaumont J, Iraburu MJ, Montiel C et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999; 17: 107-114.
35. Gimelli A, Schneider-Eicke J, Neglia D, Sambuceti G, Giorgetti A, Bigalli G et al. Homogeneously reduced versus regionally impaired myocardial blood flow in hypertensive patients: Two different patterns of myocardial perfusion associated with degree of hypertrophy. J Am Coll Cardiol 1998; 31: 366-373.
36. Sabel M, Koller BS, Sachs F, Franz MR. Stretch-induced voltage changes in the isolated beating heart: Importance of the timing of stretch and implications for stretch-activated ion channels. Cardiovasc Res 1996; 32: 120-130. Study. Lancet 2003; 362: 619-620.
37. Merri M, Moss AJ, Benhorin J, Locati EH, Albert M, Badilini F. Relation between ventricular repolarization duration and cardiac cycle length during 24-h Holter recordings. Findings in normal patients and patients with long QT syndrome. Circulation 1992; 85: 1816-1821.
38. Chevalier P, Burri H, Adeleine P, Kirkorian G, Lopez M, Leizorovicz A et al. QT dynamicity and sudden death after myocardial infarction: results of a long-term follow-up study. J Cardiovasc Electrophysiol 2003; 14: 227-233.
39. Batchvarov VN, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stabillty. Am J Physiol Heart Circ Physiol 2002; 282: H2356-H2363.
40. Franz MR, Zabel M. Electrophysiological basis of QT dispersion measurements. Progr Candiovasc Dis 2009; 42: 311-324.
41. Messerli FH, Grossman E, Goldbourt U. Are betablockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-1907.
42. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet 2004; 364: 1684-1689.
43. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: A meta-analysis. CMAJ 2006; 174: 1737-1742.
44. Lindholm LH, Dahlöf B, Edelman JE, Ibson H, borch-Johnsen K, Hecht Olson M, et al., For the LIFE study group. Effect of losartan on sudden cardiac death in people with diabetes: Data from the LIFE study. Lancet 2003; 362: 619-620.
45. Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet 2003; 362: 591-592.